Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Core Viewpoint - Legend Biotech Corporation has appointed Carlos Santos as the new Chief Financial Officer, effective immediately, succeeding Jessie Yeung who served as interim CFO since January 2025 [1][2][3] Group 1: Leadership Changes - Carlos Santos brings extensive experience in financial operations across various regions including the US, Latin America, Europe, the Middle East, and Africa [2] - Santos previously held the position of CFO for US Oncology at AstraZeneca and has a decade-long tenure there, along with roles at Alcon and Intel Corporation [3][4] - The CEO of Legend Biotech, Ying Huang, expressed confidence in Santos's financial expertise to drive the success of the company's CAR-T cell therapy franchise, CARVYKTI, and achieve profitability by 2026 [3] Group 2: Company Overview - Legend Biotech is a leading company in cell therapy with over 2,800 employees and is recognized for its innovative CAR-T cell therapy, CARVYKTI, which targets relapsed or refractory multiple myeloma [5] - The company collaborates with Johnson & Johnson for the development and marketing of CARVYKTI and aims to expand patient access and therapeutic potential [5] - Legend Biotech is focused on building a comprehensive cell therapy company and driving future innovations across its pipeline [5]